As the overall population ages, the proportion of elderly patients (aged≥ 65 years) with
breast cancer also increases. Studies have shown that elderly patients with hormone …

Background The AURELIA trial demonstrated significantly improved progression-free
survival (PFS) with bevacizumab added to chemotherapy for platinum-resistant ovarian …

Background Patients aged 65 years and older represent the majority of patients with
metastatic colorectal cancer (mCRC). However, this patient population is often …

Angiogenesis pathway genes show substantial genetic variability causing inter-individual
differences in responses to anti-angiogenic drugs. We examined 20 single nucleotide …

Although the median survival of patients with advanced disease has progressively
increased, colorectal cancer remains a major worldwide health problem, with approximately …

Although major progress has been achieved in the treatment of advanced colorectal cancer
(CRC) with the employment of antiangiogenic agents, several questions remain on the use …

Background: Although the efficacy and safety of combining first-line chemotherapy with
bevacizumab in elderly patients with colorectal cancer (CRC) is supported by the results of a …

Ovarian cancer is one of the most common gynaecological malignancies and one of the
leading causes of cancer mortality in women. The standard of care for ovarian cancer is …

The availability of new chemotherapeutic and targeted agents has changed the life
expectancy of patients with metastatic colorectal cancer thanks to the possibility of …

Osteonecrosis of the jaws is a severe bone disease. Until recently bisphosphonates were
the most common cause of drug-induced osteonecrosis of the jaws. Nowadays other drugs …